NYSE:EBS - Emergent Biosolutions Stock Price, Price Target & More

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions announced that its board has authorized a share repurchase program on Friday, March 23rd 2018, which permits the company to buyback $50,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

Emergent Biosolutions Inc (NYSE:EBS) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.25. The biopharmaceutical company earned $117.80 million during the quarter, compared to analysts' expectations of $140.42 million. Emergent Biosolutions had a net margin of 11.96% and a return on equity of 10.39%. Emergent Biosolutions's revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $0.23 EPS. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Emergent Biosolutions.

6 brokers have issued 1 year target prices for Emergent Biosolutions' stock. Their predictions range from $53.00 to $62.00. On average, they anticipate Emergent Biosolutions' stock price to reach $58.00 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Ratings for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Emergent Biosolutions include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and FibroGen (FGEN).

News coverage about EBS stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent Biosolutions earned a media sentiment score of 0.22 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Emergent Biosolutions' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.71%), Peregrine Capital Management LLC (0.66%), Boston Advisors LLC (0.24%), Bank of Montreal Can (0.14%), Foundry Partners LLC (0.11%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Fisher Asset Management LLC, Bank of Montreal Can, Peregrine Capital Management LLC, Municipal Employees Retirement System of Michigan, Foundry Partners LLC and Capital Asset Advisory Services LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was bought by a variety of institutional investors in the last quarter, including First National Bank of Omaha, Hartford Investment Management Co., Xact Kapitalforvaltning AB and Amalgamated Bank. View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $54.26.

Emergent Biosolutions has a market capitalization of $2.70 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]